About Attenuon
Attenuon is a San Diego-based clinical-stage biopharmaceutical company developing a
new generation of cancer therapeutics. Attenuon’s compounds – two of which are
currently in Phase II clinical trials – are intended to target a broad range of tumors and
the blood vessels that feed their growth without affecting healthy cells. These drug
candidates have the potential to be effective against many types of cancer, produce few
side effects, and be suitable for long-term use. For more information, please visit the
company's website at
www.attenuon.com.
About XOMA
XOMA is a leader in the discovery, development and manufacture of therapeutic
antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA
has royalty interests in RAPTIVA® (efalizumab), a monoclonal antibody product
marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe
plaque psoriasis, and LUCENTISTM (ranibizumab injection), a monoclonal antibody
product marketed worldwide (by Genentech and Novartis AG) to treat neovascular (wet)
age-related macular degeneration.
The company has built a premier antibody discovery and development platform that
includes access to seven of the leading commercially available antibody phage display
libraries and XOMA’s proprietary Human EngineeringTM and bacterial cell expression
(BCE) technologies. More than 45 companies have signed BCE licenses. XOMA’s
development collaborators include Lexicon Genetics, Inc., Novartis, and Schering-Plough
Corporation. With a fully integrated product development infrastructure, XOMA’s
product development capabilities extend from preclinical sciences to product launch. For
more information, please visit the company's website at
www.xoma.com.